LEADER 05005nam 2200577 450 001 9910137534203321 005 20230621140728.0 010 $a9782889195527 (ebook) 035 $a(CKB)3710000000569658 035 $a(SSID)ssj0001669394 035 $a(PQKBManifestationID)16459983 035 $a(PQKBTitleCode)TC0001669394 035 $a(PQKBWorkID)15003731 035 $a(PQKB)11697395 035 $a(WaSeSS)IndRDA00056663 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/44031 035 $a(EXLCZ)993710000000569658 100 $a20160829d2015 uy | 101 0 $aeng 135 $aur||||||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aControl of visceral leishmaniasis by immunotherapeutic and prophylactic strategies$b[electronic resource] /$fedited by Nahid Ali, Hira L. Nakhasi, Jesus G. Valenzuela and Alexandre Barbosa Reis 210 $cFrontiers Media SA$d2015 210 1$aFrance :$cFrontiers Media SA,$d2015 215 $a1 online resource (144 pages) $cillustrations, charts 225 0 $aFrontiers Research Topics 300 $aBibliographic Level Mode of Issuance: Monograph 320 $aIncludes bibliographical references. 330 $aVisceral leishmaniasis (VL) or kala-azar is the most dreadful of all forms of leishmaniasis caused by Leishmania donovani in Old World and Leishmania chagasi and/or Leishmania infantum in New World affecting millions of people worldwide. In active VL, macrophages host the replicating amastigotes in phagolysosomal compartments leading to splenomegaly, hepatomegaly, hyperglobulinemia, anemia, weight-loss, incessant fever and ultimately death if not treated. Treatments available against the disease are limited by increased incidence of resistance, serious side-effects, high cost and long course of treatment. Immuno-chemotherapy is an alternative to overcome the limitations of the drugs against VL. Combination of one or more of immunotherapeutic agents like BCG, Alum, IFN-?, antigen-pulsed dendritic cells (DC), etc. with chemotherapeutic drugs have been tested raising hopes for a suitable immuno-chemotherapy against VL and Post Kala-azar Dermal Leishmaniasis (PKDL). Antagonists of IL-10, TGF-ß, IL-13 have been effectively used with pentavalent antimonials in treatment of experimental VL. Some parasitic antigens and liposomal formulations have also been shown to impart superior therapeutic effectiveness to antileishmanial drugs. For socio-economic reasons prophylaxis is always more desirable than therapy. Although no vaccine against any form of leishmaniasis in humans is available, patients successfully treated show considerable protection from reinfection highlighting the possibility of developing prophylactic measures against the disease. Subsequently a lot of interest has been focused recently towards developing vaccines against VL and many potential vaccine candidates like whole cell (attenuated or heat killed), crude fractions, purified subunits, DNAs, recombinant proteins, fusion proteins, and genetically modified live attenuated parasites etc. have been reported. These vaccine candidates are either activators of CD4+Th1 cells and/or CD8+ T cells or neutralizers of immuno-suppression. Cationic liposomal formulations, nanoparticle and virosome delivery systems, etc. have been used to increase potency and durability of various vaccine candidates. Immuno-modulators like TLR agonists have been shown to be promising adjuvants in enhancing efficacy and overcoming the challenge of human administrable vaccine formulations. Recently role of sand fly salivary gland proteins as immune-modulators also has been explored. Various strategies such as heterologous prime boosting, targeted antigen delivery, adjuvant mediated protection, have been undertaken. Likewise, precise role of regulatory T cells (Tregs) in VL disease progression needs to be investigated and exploited to develop both immuno-therapeutic and prophylactic methods. A breakthrough in immunotherapy and prophylactic strategy would help in eradication of the parasites from the pool of natural reservoirs namely VL and PKDL patients, asymptomatic carrier individuals and infected dogs ensuring success of global VL control programs. 606 $aAlternative Medicine$2HILCC 606 $aMedicine$2HILCC 606 $aHealth & Biological Sciences$2HILCC 610 $aImmuno modulator 610 $aTh1 response 610 $aVisceral leishmaniasis 610 $aImmunotherapy 610 $aVaccine 615 7$aAlternative Medicine 615 7$aMedicine 615 7$aHealth & Biological Sciences 700 $aAlexandre Barbosa Reis$4auth$01364682 702 $aNakhasi$b Hira L 702 $aAli$b Nahid 702 $aValenzuela$b Jesus G 801 0$bPQKB 801 2$bUkMaJRU 912 $a9910137534203321 996 $aControl of visceral leishmaniasis by immunotherapeutic and prophylactic strategies$93386201 997 $aUNINA LEADER 04274nam 22006735 450 001 9910720069203321 005 20251008143543.0 010 $a3-031-26576-9 024 7 $a10.1007/978-3-031-26576-1 035 $a(MiAaPQ)EBC7243087 035 $a(Au-PeEL)EBL7243087 035 $a(DE-He213)978-3-031-26576-1 035 $a(OCoLC)1378935182 035 $a(PPN)269655794 035 $a(CKB)26540738800041 035 $a(EXLCZ)9926540738800041 100 $a20230429d2023 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aBiochemistry and Cell Biology of Ageing: Part IV, Clinical Science /$fedited by J. Robin Harris, Viktor I. Korolchuk 205 $a1st ed. 2023. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2023. 215 $a1 online resource (458 pages) 225 1 $aSubcellular Biochemistry,$x2542-8810 ;$v103 311 08$a3-031-26578-5 311 08$a3-031-26575-0 320 $aIncludes bibliographical references. 327 $aChapter 1:Introduction: Historical Development and Progression of Clinical Research on Ageing -- Chapter 2:Bone Cells Metabolic Changes Induced by Ageing -- Chapter 3:Chronic Inflammation as an Underlying Mechanism of Ageing and Ageing-related Diseases -- Chapter 4: Heart Disease and Ageing: The roles of Senescence, Mitochondria and Telomerase in Cardiovascular Disease -- Chapter 5: Chronic Kidney Disease and the Exposome of Ageing -- Chapter 6: Sarcopenia and Ageing -- Chapter 7: Tendon Ageing -- Chapter 8: Virus Infections in Older People -- Chapter 9: Models and Biomarkers for Ovarian Ageing -- Chapter 10: Ageing and the Autonomic Nervous System -- Chapter 11: Astrocytes in Ageing -- Chapter 12: Hearing and Ageing -- Chapter 13: Melatonin and Ageing -- Chapter 14: Protein and Energy Supplements for the Elderly -- Chapter 15: Ageing, Metabolic Dysfunction, and the Therapeutic Role of Antioxidants -- Chapter 16: Clinical Ageing. 330 $aThis book provides an up-to-date overview of key areas of ageing research and bridges the gap between the subcellular events and the reality of ageing as seen in clinical practice. To this end, the reader learns about the historical development and progression of clinical ageing research. All chapters address the biochemistry or cell biology of various ageing events (to the extent that the data are available) and work their way to the clinical understanding we have of ageing. The focus of this volume is on how dietary restriction, virus infection and chronic inflammation affect the ageing process. Additionally, this book discusses how phosphate metabolism and metabolic dysfunction contribute to ageing events and how various organs and tissues (e.g. tendons, ears, heart muscle, and the endocrine system) age. This book follows on from Parts I, II and III of Biochemistry and Cell Biology of Ageing within the Subcellular Biochemistry book seriesand aims to bring the subcellular and clinical areas into closer contact by including interesting and significant biomedical ageing topics that were not included in the earlier volumes. Comprehensive and cutting-edge, this book is a valuable resource for experienced researchers and early career scientist alike, who are interested in learning more about the fascinating and challenging question of why and how our cells age. 410 0$aSubcellular Biochemistry,$x2542-8810 ;$v103 606 $aAging 606 $aCytology 606 $aClinical biochemistry 606 $aProteins 606 $aAgeing 606 $aCell Biology 606 $aMedical Biochemistry 606 $aProtein Biochemistry 615 0$aAging. 615 0$aCytology. 615 0$aClinical biochemistry. 615 0$aProteins. 615 14$aAgeing. 615 24$aCell Biology. 615 24$aMedical Biochemistry. 615 24$aProtein Biochemistry. 676 $a612.67 702 $aHarris$b J. Robin 702 $aKorolchuk$b Viktor I. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910720069203321 996 $aBiochemistry and Cell Biology of Ageing$91945703 997 $aUNINA